+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stimulation of in-vitro angiogenesis by low concentrations of risedronate is mitigated by 1,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3

Stimulation of in-vitro angiogenesis by low concentrations of risedronate is mitigated by 1,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3

Journal of Steroid Biochemistry and Molecular Biology 148: 214-218

The nitrogen-containing or nitrogenous bisphosphonates (N-BF) are currently the main class of drugs used for the treatment of diseases characterized by an increased bone resorption. Preliminary data suggest that N-BF have also direct or indirect anti-tumoral effects, and recent evidence suggests that part of the anti-tumoral activity of N-BF may be attributed to their anti-angiogenic capacity when they are used at high concentrations. On the other hand, an optimal vitamin-D status seems to be necessary to maximize the bone response to N-BF. Our aim has been to evaluate the effect of risedronate, alone or in combination with either 1,25(OH)2D3 or 24,25(OH)2D3 (two main vitamin-D metabolites) on parameters related to the angiogenic capacity of human umbilical-vein endothelial cells (HUVEC). The studies of tube formation through in-vitro angiogenesis assays with Matrigel, chemotaxis and migration in a scratch assay showed that low concentrations of risedronate (0.01 to 1μM) stimulated angiogenesis and cellular migration in vitro. The presence of 1,25(OH)2D3 in the medium inhibited tubular-structure formation and cellular migration. In addition, the presence of 1,25 or 24,25(OH)2D3 in the culture medium also decreased the pro-angiogenic effects of low-concentrations of risedronate. These data show the differential effects of different concentrations of vitamin-D metabolites and risedronate on angiogenesis, thus stressing the importance of an adequate vitamin D status during medical treatment with risedronate. This article is part of a Special Issue entitled '17th Vitamin D Workshop'.

(PDF emailed within 0-6 h: $19.90)

Accession: 058905934

Download citation: RISBibTeXText

PMID: 25445918

DOI: 10.1016/j.jsbmb.2014.10.018

Related references

Plasma concentrations of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25,26-dihydroxyvitamin D in the first year of life. Journal of Clinical Endocrinology and Metabolism 57(4): 755-759, 1983

Effects of continuous administration of 1,25-dihydroxyvitamin D3 on plasma minerals and unoccupied colon mucosal 1,25-dihydroxyvitamin D3 receptor concentrations. Journal of Dairy Science 72(11): 2936-2941, 1989

Bone marrow and serum concentrations of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1 alpha,25-dihydroxyvitamin D in patients with leukemia and normal subjects. Journal of Nutritional Science and Vitaminology 35(4): 211-223, 1989

The effects of high doses of 24 25 dihydroxyvitamin d 3 and a combined dose of 1 25 dihydroxyvitamin d 3 and 24 25 dihydroxyvitamin d 3 on developing bone in rats. Calcified Tissue International 44(SUPPL): S-27, 1989

Failure of pharmacologic doses of 1,25-dihydroxyvitamin D3, 24-F-1,25-dihydroxyvitamin D3 and 24, 24-F2-1,25-dihydroxyvitamin D3 to stimulate bone resorption in dairy cows.. Calcified Tissue International 36(4): 514, 1984

Stimulation of 1 25 dihydroxyvitamin d 3 clearance but not intestinal c 24 oxidation by physiological levels of 1 25 dihydroxyvitamin d 3 in rats. Journal of the American Society of Nephrology 2(3): 635, 1991

Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat. Biochemical Pharmacology 60(5): 701-708, 2000

Effect of 24 25 dihydroxyvitamin d 3 on 1 25 dihydroxyvitamin d 3 metabolism in vitamin d deficient rats infused with 1 25 dihydroxyvitamin d 3. Endocrinology 124(1): 511-517, 1989

25 dihydroxyvitamin d 3 and 1 24 dihydroxyvitamin d 3 suppress in vitro antibody response to t cell dependent antigen. Biochemical & Biophysical Research Communications: 753-758, 1985

1,25-Dihydroxyvitamin D3 and 1,24-dihydroxyvitamin D3 suppress in vitro antibody response to T cell-dependent antigen. Biochemical and Biophysical Research Communications 127(3): 753-758, 1985

1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 281(5729): 317-319, 1979

In vitro synthesis of 1 25 dihydroxyvitamin d 3 and 24 25 dihydroxyvitamin d 3 by fetal and maternal sheep kidneys. Pediatric Research 19(4 PART 2): 192A, 1985

A direct effect of 24 25 dihydroxyvitamin d 3 and 1 25 dihydroxyvitamin d 3 on the modeling of fetal mice long bones in vitro. Journal of Bone & Mineral Research 4(2): 157-164, 1989

19nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 in vivo and in vitro. Molecular Pharmacology 69(5): 1740-1747, 2006

The 1,25-dihydroxyvitamin D3 receptor is phosphorylated in response to 1,25-dihydroxyvitamin D-3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro. Biochemistry 32(32): 8184-8192, 1993